MedTrace Logo

The Role of KL-6 in the Clinical Diagnosis of ILD

NCT02197364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1190

Last updated 2014-07-22

No results posted yet for this study

Summary

The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases. In addition, the study discusses the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and after treatment.

Conditions

Sponsors & Collaborators

  • Fujirebio Diagnostics, Inc.

    collaborator INDUSTRY

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Li Hui Ping · Shanghai Pulmonary Hospital , Tongji University

Eligibility

Min Age
14 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-04-30
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197364 on ClinicalTrials.gov